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Abstract
Multiple sclerosis (MS) remains without an effective treatment in spite of intense research efforts.
Interferon-beta (IFN-β) reduces duration and severity of symptoms in many relapsing-remitting MS
patients, but its mechanism of action is still not well understood. Moreover, IFN-β and other
available treatments must be given parenterally and have a variety of adverse effects. Certain
naturally occurring flavonoids, such as luteolin, have anti-oxidant and anti-inflammatory effects,
including inhibition of activated peripheral blood leukocytes from MS patients. Luteolin also inhibits
mast cells, as well as mast cell-dependent T cell activation, recently implicated in MS pathogenesis.
Moreover, luteolin and structurally similar flavonoids can inhibit experimental allergic allergic
encephalomyelitis (EAE), an animal model of MS in rodents. An appropriate luteolin formulation
that permits sufficient absorption and reduces its metabolism could be a useful adjuvant to IFN-β
for MS therapy.
Introduction
This issue includes an interesting article by Sternberg et al.
showing that the flavonoid luteolin inhibits IL-1, TNF and
metalloproteinase-9 (MMP-9) release from activated
peripheral blood mononuclear cells (PBMCs) from multi-
ple sclerosis (MS) patients, and that the effect of luteolin
is augmented by concurrent administration of interferon-
beta (IFN-β). This paper extends previous similar results
with quercetin that required higher concentrations of the
flavonoid [1].
Discussion
Luteolin with or without IFN-β, could be helpful in MS by
not only inhibiting PBMC release of cytokines, but also by
inhibiting T cells, which we recently showed can be super-
stimulated by mast cells, an action also inhibited by lute-
olin [2]. In addition to T cells, recent evidence implicates
also TH2 processes typically associated with allergic reac-
tions [3-5], which involve mast cells (Fig. 1). In fact, mast
cells have been considered as the next target for MS ther-
apy [6-8].
Brain MS plaques also contain activated mast cells [9,10],
which have been associated with brain demyelination
[11-13]. Gene array analysis also showed that MS plaques
had increased gene expression for the IgE receptor (FcεRI),
the histamine-1 receptor and the protease tryptase, all of
which are associated with mast cells [14-16]. Mast cell
tryptase is elevated in the CSF of MS patients [17], can
activate peripheral mononuclear cells to secrete TNF and
IL-6 [18], as well as stimulate protease-activated receptors
(PAR) to induce widespread inflammation [19]. Brain
mast cells can secrete TNF [20], which is involved in both
brain inflammation [21] and blood-brain-barrier (BBB)
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permeability [22]. In fact, BBB disruption precedes any
pathologic signs of MS [23] and mast cells can disrupt the
BBB [24,25].
Flavonoids such as quercetin have potent anti-oxidant
and anti-inflammatory activity [26]. Quercetin and luteo-
lin also inhibit human cultured mast cell release of hista-
mine, leukotrienes and prostaglandin D2 [27], as well as
IL-6, IL-8, TNF-α and tryptase [28,29]. Moreover, querce-
tin and luteolin inhibit mast cell activation stimulated by
IL-1 [30] leading to selective release of IL-6. Luteolin also
inhibits IL-6 release from microglia cells [31], and from
astrocytes [32]. Flavonoids can also inhibit myelin phago-
cytosis by macrophages [33], as well as inhibit EAE [34-
36].
Conclusion
Quercetin and its structurally related luteolin are safe [37].
The fact remains that less than 10% of flavonoids are
absorbed orally [37]. Novel ways of delivering select fla-
vonoid combinations would be required to assure suffi-
cient plasma levels, especially if luteolin were to also
inhibit brain inflammation. Such a test nutraceutical for-
mulation has already been tried on a number of relapsing-
remitting MS patients treated with INF-β with encourag-
ing positive results.
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